Insmed is a New Jersey-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of lung and inflammatory diseases.
Business Model:
Revenue: $242.2M
Employees: 501-1,000
Address: 700 US Highway
City: Bridgewater
State: NJ
Zip: 08807
Country: US
Insmed is a New Jersey-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of lung and inflammatory diseases.
Contact Phone:
+19089779900
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
6/9/2000
Ticker Symbol:
INSM
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2000 | IPO | - | 3/2015 | Post-IPO Equity | 1 | - |
Forbion Capital Partners Forbion Capital Partners |
9/2017 | Post-IPO Equity | $377.7M | 6/2019 | Secondary Offering | $261.1M | 5/2019 | Post-IPO Equity | $235.5M | 5/2020 | Post-IPO Equity | $259.4M | 5/2021 | Post-IPO Equity | $575M | 6/2019 | Post-IPO Equity | $25.6M | 10/2022 | Post-IPO Equity | $275M | 1/2018 | Post-IPO Debt | $435.8M | 10/2022 | Post-IPO Debt | 2 | $500M |
OrbiMed Pharmakon Advisors OrbiMed Pharmakon Advisors |
3/2005 | Post-IPO Debt | $32.8M | 5/2000 | IPO | - | 3/2015 | Post-IPO Equity | 1 | - |
Forbion Capital Partners Forbion Capital Partners |
---|
Announced Date | Name | Price |
---|---|---|
12/2010 | Transave | |
5/2000 | Celtrix Pharmaceuticals |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|